---

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

---

FORM 8-K

 

---

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

June 25, 2007

Date of Report (Date of earliest event reported)

 

---

ANTIGENICS INC.

(Exact name of registrant as specified in its charter)

 

---

 

DELAWARE		000-29089		06-1562417
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

 

162 Fifth Avenue, Suite 900 New York, NY		10010
(Address of principal executive offices)		(Zip Code)

 

212-994-8200

(Registrant’s telephone number, including area code)

 

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

---

---

Item 8.01

Other Events

On June 25, 2007, Antigenics completed the submission of an application for marketing authorization with the Russian Ministry of Public Health for the use of Oncophage^® (vitespen) in the treatment of kidney cancer patients at intermediate risk for disease recurrence.

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

				ANTIGENICS INC.
Date: June 26, 2007				By:		/s/ Garo H. Armen, Ph.D.
						Garo H. Armen, Ph.D.
						Chairman and Chief Executive Officer